Gapping down
In reaction to disappointing earnings/guidance: ATEA -19.8%, SCOK -13.7%, ROX -13.6%, VPCO -3.3%, SVA -2.9%, RNA -2.5%
M&A news: DWA -13.7% (Dreamworks Animation and Hasbro (HAS) M&A talks may be fading, according to reports), HAL -4% (Baker Hughes & Halliburton (HAL) to combine in stock and cash transaction valued at $34.6 bln or $78.62/ BHI share), VRX -1.3% says if they are not successful in removing a majority of directors in order to facilitate negotiations, they will likely retract their offer for AGN)
Select metals/mining stocks trading lower: HMY -4%, GFI -2.3%, AU -2.2%, AU -2.2%, GOLD -1.1%, SLV -1%
Select oil/gas related names showing early weakness: PTR -2%, PBR -1.4%, STO -1%, BP -0.9%, TOT -0.7%
Other news: GSAT -12.5% (stock fell in after-hours Friday as Cramer was no longer bullish on Mad Money; note that CEO disclosed stock purchases this morning), INO -11.8% (to independently develop prostate cancer immunotherapy; will maintain collaboration and license agreement with Roche (RHHBY) for Inovio's Hepatitis B Immunotherapy), DNR -6.5% (announces management changes and key elements of the company's plans for 2015 that will be presented at their annual analyst day; also downgraded to Neutral from Outperform at Credit Suisse), JRJC -2.7% (announces change in auditing firm), LNKD -2.5% (may be attributed to article in FT FT that Facebook (FB) may introduce ‘Facebook at Work' website), LOCO -2.4% (commenced a proposed public follow-on offering on behalf of certain of the company's stockholders to offer 6 mln shares of the company's common stock), AZN -2.2% (presents data from Phase III studies of Lesinurad in combination with Allopurinol in gout patients), MU -2.1% (still checking), TSEM -1.7% (still checking), PFE -1.6% (still checking), PFE -1.6% (forms global strategic alliance with Merck KGaA (MKGAY.PK) to jointly develop and commercialize anti-PD-L1 to accelerate presence in immuno-oncology), SNE -1.4% (weak mkts in Japan overnight), YELP -1.4% (still checking), TM -1.3% (weak mkts in Japan overnight), DE -1% (Berkshire Hathaway sells position in DE; prior stake was around 4 mln shares)
Analyst comments: TUBE -2.7% (downgraded to Neutral from Buy at Citigroup), ODP -2.2% (downgraded to Neutral from Buy at Goldman), NOK -2% (downgraded to Underperform from Mkt Perform at Raymond James), IMPV -1.3% (downgraded to Neutral from Overweight at JP Morgan), KMX -1.3% (downgraded to Equal-Weight from Overweight at Morgan Stanley), HTZ -1.3% (downgraded to Market Perform from Outperform at Wells Fargo), AEG -1.2% (downgraded to Neutral from Buy at BofA/Merrill
)
In reaction to disappointing earnings/guidance: ATEA -19.8%, SCOK -13.7%, ROX -13.6%, VPCO -3.3%, SVA -2.9%, RNA -2.5%
M&A news: DWA -13.7% (Dreamworks Animation and Hasbro (HAS) M&A talks may be fading, according to reports), HAL -4% (Baker Hughes & Halliburton (HAL) to combine in stock and cash transaction valued at $34.6 bln or $78.62/ BHI share), VRX -1.3% says if they are not successful in removing a majority of directors in order to facilitate negotiations, they will likely retract their offer for AGN)
Select metals/mining stocks trading lower: HMY -4%, GFI -2.3%, AU -2.2%, AU -2.2%, GOLD -1.1%, SLV -1%
Select oil/gas related names showing early weakness: PTR -2%, PBR -1.4%, STO -1%, BP -0.9%, TOT -0.7%
Other news: GSAT -12.5% (stock fell in after-hours Friday as Cramer was no longer bullish on Mad Money; note that CEO disclosed stock purchases this morning), INO -11.8% (to independently develop prostate cancer immunotherapy; will maintain collaboration and license agreement with Roche (RHHBY) for Inovio's Hepatitis B Immunotherapy), DNR -6.5% (announces management changes and key elements of the company's plans for 2015 that will be presented at their annual analyst day; also downgraded to Neutral from Outperform at Credit Suisse), JRJC -2.7% (announces change in auditing firm), LNKD -2.5% (may be attributed to article in FT FT that Facebook (FB) may introduce ‘Facebook at Work' website), LOCO -2.4% (commenced a proposed public follow-on offering on behalf of certain of the company's stockholders to offer 6 mln shares of the company's common stock), AZN -2.2% (presents data from Phase III studies of Lesinurad in combination with Allopurinol in gout patients), MU -2.1% (still checking), TSEM -1.7% (still checking), PFE -1.6% (still checking), PFE -1.6% (forms global strategic alliance with Merck KGaA (MKGAY.PK) to jointly develop and commercialize anti-PD-L1 to accelerate presence in immuno-oncology), SNE -1.4% (weak mkts in Japan overnight), YELP -1.4% (still checking), TM -1.3% (weak mkts in Japan overnight), DE -1% (Berkshire Hathaway sells position in DE; prior stake was around 4 mln shares)
Analyst comments: TUBE -2.7% (downgraded to Neutral from Buy at Citigroup), ODP -2.2% (downgraded to Neutral from Buy at Goldman), NOK -2% (downgraded to Underperform from Mkt Perform at Raymond James), IMPV -1.3% (downgraded to Neutral from Overweight at JP Morgan), KMX -1.3% (downgraded to Equal-Weight from Overweight at Morgan Stanley), HTZ -1.3% (downgraded to Market Perform from Outperform at Wells Fargo), AEG -1.2% (downgraded to Neutral from Buy at BofA/Merrill
)